CFAP20DC and breast carcinoma: Ginsenoside (Rh2) plays an essential role in breast cancer treatment because it could downregulate C3orf67-AS1 by persuading the hypermethylation of the C3orf67-AS1 promoter in MCF-7 cells [145].